Pro Medicus Ltd (ASX: PME) shares are rising on Friday following another major contract announcement.
The medical imaging technology company has secured a $128 million agreement in the United States, adding to its growing list of customer wins.
But does this latest deal make Pro Medicus shares a strong buy? Here's how I see things.
This morning, Pro Medicus announced that it has signed a 10-year, $128 million contract with NYC Health + Hospitals.
This is a significant customer win. NYC Health + Hospitals is the largest municipal healthcare system in the United States, serving more than 1 million patients annually across more than 70 locations.
Under the agreement, Pro Medicus will provide its complete Visage 7 enterprise imaging platform, including its Viewer, Workflow, and Open Archive products.
The software will be deployed through the cloud, with operations expected to commence in the third quarter of calendar year 2027.
Importantly, the agreement is based on a transaction-based licensing model, with potential upside beyond the announced contract value.
This means Pro Medicus could generate additional revenue if imaging volumes exceed expectations.
I think the latest agreement reinforces several reasons why Pro Medicus remains one of my favourite ASX growth shares.
Firstly, securing a contract with such a large healthcare organisation demonstrates the strength of its technology.
The company is competing in an industry where reliability, speed, and integration with existing hospital systems are essential.
And winning a major public healthcare customer could strengthen its credentials when pursuing other large contracts.
Secondly, I like the long-term revenue opportunity. Spread evenly over 10 years, the agreement represents approximately $12.8 million annually. I calculate this to be the equivalent of almost 5% of Pro Medicus' FY26 revenue of $261.7 million.
Actual revenue will depend on transaction volumes and the implementation timetable, but it provides another substantial contribution to the company's growing contracted revenue base.
And this follows an impressive FY26, when Pro Medicus secured 10 new contracts worth a combined minimum of $407 million.
I would be happy to buy Pro Medicus shares following today's announcement.
The company continues to demonstrate its ability to win major healthcare contracts, while its high profit margins suggest that additional revenue could translate into substantial earnings growth.
The main consideration is valuation. Pro Medicus shares have historically traded at a considerable premium, and investors are already expecting strong growth.
Any disappointing results or implementation delays could therefore create volatility.
Nevertheless, I think its competitive position and expanding customer base justify a positive long-term outlook.
I see today's $128 million contract as another reason to remain optimistic about Pro Medicus.
The company is steadily building relationships with some of the world's largest healthcare organisations, and those relationships can generate revenue for many years.
For investors willing to look beyond short-term share price fluctuations, I think Pro Medicus remains a strong long-term buy.
The post $128 million contract win: Are Pro Medicus shares a strong buy? appeared first on The Motley Fool Australia.
Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026